Global Medical REIT (NYSE:GMRE) Updates FY 2026 Earnings Guidance

Global Medical REIT (NYSE:GMRE) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.300-4.450 for the period, compared to the consensus earnings per share estimate of 1.740. The company issued revenue guidance of -.

Global Medical REIT Stock Performance

Shares of Global Medical REIT stock traded down $0.03 during trading on Wednesday, reaching $35.96. The company’s stock had a trading volume of 72,688 shares, compared to its average volume of 79,476. The company has a quick ratio of 0.52, a current ratio of 0.52 and a debt-to-equity ratio of 1.65. The business’s 50-day moving average price is $35.18 and its 200-day moving average price is $34.35. Global Medical REIT has a 52 week low of $29.05 and a 52 week high of $45.75. The firm has a market cap of $482.22 million, a PE ratio of -143.84 and a beta of 1.18.

Global Medical REIT Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 9th. Shareholders of record on Friday, December 19th were given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 8.3%. The ex-dividend date was Friday, December 19th. Global Medical REIT’s dividend payout ratio is presently -1,200.00%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GMRE. Weiss Ratings upgraded shares of Global Medical REIT from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, January 21st. Robert W. Baird cut their target price on Global Medical REIT from $45.00 to $41.00 and set a “neutral” rating for the company in a research report on Tuesday, November 11th. Finally, Wall Street Zen lowered Global Medical REIT from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Institutional Investors Weigh In On Global Medical REIT

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. increased its holdings in Global Medical REIT by 30.5% during the 2nd quarter. Invesco Ltd. now owns 1,518,668 shares of the company’s stock worth $10,524,000 after acquiring an additional 355,355 shares during the period. Alyeska Investment Group L.P. purchased a new position in shares of Global Medical REIT during the 3rd quarter valued at $9,997,000. Marshall Wace LLP increased its holdings in shares of Global Medical REIT by 2,208.2% in the second quarter. Marshall Wace LLP now owns 291,708 shares of the company’s stock worth $2,022,000 after purchasing an additional 279,070 shares during the period. Hotchkis & Wiley Capital Management LLC purchased a new stake in shares of Global Medical REIT in the third quarter worth $7,798,000. Finally, AXA S.A. purchased a new stake in shares of Global Medical REIT in the second quarter worth $1,016,000. 57.52% of the stock is currently owned by institutional investors.

About Global Medical REIT

Global Medical REIT (NYSE: GMRE) is a real estate investment trust focused on owning and managing healthcare-related properties across the United States. The company acquires, develops and leases a diversified portfolio of medical office buildings, outpatient facilities, long-term care centers and other specialized healthcare real estate. By concentrating on essential healthcare assets, Global Medical REIT seeks to generate stable, long-term rental income under triple-net and modified gross lease structures.

Since its incorporation in 2016 and initial public offering in 2017, the company has pursued an acquisitive growth strategy targeting markets with strong demographic trends and limited supply of modern medical facilities.